Published in Cancer Res on October 01, 2008
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood (2010) 1.75
Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett (2014) 1.29
Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux. J Cell Sci (2009) 1.20
A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene (2010) 1.17
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy. Clin Cancer Res (2010) 1.08
Dual functions of autophagy in the response of breast tumor cells to radiation: cytoprotective autophagy with radiation alone and cytotoxic autophagy in radiosensitization by vitamin D 3. Autophagy (2012) 1.07
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet (2012) 1.07
Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. PLoS One (2012) 1.03
20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget (2014) 0.95
Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat (2011) 0.91
Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. Chin J Cancer (2011) 0.88
Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J Cancer Res Clin Oncol (2010) 0.88
Roscovitine in cancer and other diseases. Ann Transl Med (2015) 0.86
Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer (2013) 0.85
PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. J Transl Med (2016) 0.82
PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells. Int J Oncol (2010) 0.81
The HDAC inhibitor Vorinostat diminishes the in vitro metastatic behavior of Osteosarcoma cells. Biomed Res Int (2015) 0.80
Radiation-induced autophagy contributes to cell death and induces apoptosis partly in malignant glioma cells. Cancer Res Treat (2014) 0.78
Inflammatory stress and sarcomagenesis: a vicious interplay. Cell Stress Chaperones (2013) 0.77
Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget (2015) 0.77
Blue-Print Autophagy: Potential for Cancer Treatment. Mar Drugs (2016) 0.77
The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. Front Oncol (2015) 0.76
Galectin-3 and Beclin1/Atg6 genes in human cancers: using cDNA tissue panel, qRT-PCR, and logistic regression model to identify cancer cell biomarkers. PLoS One (2011) 0.76
Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther (2016) 0.76
Imatinib mesylate decreases the cytotoxic effect of roscovitine on human glioblastoma cells in vitro and the role of midkine. Oncol Lett (2011) 0.75
MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma. Mol Med Rep (2017) 0.75
Antitumor activity of cobrotoxin in human lung adenocarcinoma A549 cells and following transplantation in nude mice. Oncol Lett (2014) 0.75
The flavonoid luteolin enhances doxorubicin-induced autophagy in human osteosarcoma U2OS cells. Int J Clin Exp Med (2015) 0.75
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine. Sultan Qaboos Univ Med J (2011) 0.75
Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells. PLoS One (2016) 0.75
Conventional osteosarcoma of the mandible successfully treated with radical surgery and adjuvant chemotherapy after responding poorly to neoadjuvant chemotherapy: a case report. J Med Case Rep (2017) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
G1 phase progression: cycling on cue. Cell (1994) 11.62
Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol (2001) 9.18
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem (1997) 6.99
A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res (2001) 5.92
Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol (2005) 5.80
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad Sci U S A (2006) 5.16
A family of human cdc2-related protein kinases. EMBO J (1992) 4.96
Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol (1998) 4.54
A unified view of the DNA-damage checkpoint. Curr Opin Cell Biol (2002) 4.10
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. Cancer Cell (2005) 3.69
Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol (2007) 2.70
Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg (1990) 2.17
A p34(cdc2) survival checkpoint in cancer. Cancer Cell (2002) 1.99
Construction by gene targeting in human cells of a "conditional' CDC2 mutant that rereplicates its DNA. Nat Genet (1997) 1.98
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res (2003) 1.88
Deregulation of cyclin E in breast cancer. Oncogene (1995) 1.78
Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells. Mol Cancer Ther (2006) 1.76
Management of soft-tissue sarcomas: an overview and update. Lancet Oncol (2000) 1.76
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
The epidemiology of soft tissue sarcoma. Semin Oncol (1997) 1.62
Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol (1992) 1.58
Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene (1998) 1.35
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. J Biol Chem (2002) 1.29
E2F-1 induced apoptosis. Apoptosis (2001) 1.22
Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res (1999) 1.22
Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J Cell Sci (1995) 0.97
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene (2004) 0.91
Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy. Clin Cancer Res (2005) 0.88
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA (2011) 16.68
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2003) 12.94
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13
Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol (2007) 4.05
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell (2007) 3.84
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res (2005) 3.80
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A (2010) 3.03
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys (2004) 3.00
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol (2007) 2.72
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol (2006) 2.69
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ (2002) 2.53
Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol (2008) 2.51
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol (2006) 2.43
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol (2012) 2.40
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol (2008) 2.39
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res (2002) 2.37
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res (2004) 2.32
Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA (2011) 2.28
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res (2007) 2.28
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Imaging features of primary breast sarcoma. AJR Am J Roentgenol (2012) 2.26